secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211904
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT Q1 net loss $68.8M; cash $458M; 4D-150 Phase 3 enrollment complete
-----------------------------------------------------------------------

- Cash $458M as of Mar 31, 2026, down from $514M; expected to fund ops into H2 2028.
- Net loss $68.8M vs $48.0M YoY; R&D expenses rose to $65.0M on Phase 3 trial execution.
- 4D-150 wet AMD Phase 3 (4FRONT-1) randomization complete (N=523); topline data H1 2027.
- PRISM Phase 2b 2-year data for wet AMD expected at a conference Q3 2026; SPECTRA DME 2-year data H2 2026.
- 4D-710 (CF) AEROW trial update expected H2 2026; 4D-175 (GA) evaluating strategic funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/0001193125-26-211904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/fdmt-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer